Vilaprisan


Vilaprisan is a synthetic and steroidal selective progesterone receptor modulator which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids. It is a potent and highly selective partial agonist of the progesterone receptor. As of 2017, the drug is in phase II clinical trials for the aforementioned indications.